MedTrace Logo

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 196

Last updated 2024-02-21

No results posted yet for this study

Summary

This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole. Patients who present for treatment of a first psychotic episode with a schizophrenia spectrum diagnosis and who are eligible to undergo treatment with either risperidone or aripiprazole will be offered participation in the study. Clinical ratings, neuropsychological testing, neuroimaging and EEG will be conducted at baseline. Additionally, subjects will undergo the same assessments at week 12 to determine treatment-related biomarkers. Clinical ratings, including neurocognitive testing, will be conducted by blinded raters at study visits during treatment. Healthy controls (N=50) will also be recruited and scanned twice (12-week interval) to control for effects of time and practice.

Conditions

  • Psychotic Disorders

Interventions

DRUG

Risperidone or Aripiprazole (patients only)

Inpatients deemed eligible for the study, we be put on open-label risperidone

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Northwell Health

    lead OTHER

Principal Investigators

  • Anil Malhotra, MD · The Zucker Hillside Hospital

Eligibility

Min Age
15 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02822092 on ClinicalTrials.gov